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Abstract: The I148M variant of the Patatin-like phospholipase domain-containing 3 (PNPLA3) protein
is associated with an increased risk for liver inflammation and hepatocellular carcinoma (HCC), but the
underlying mechanism is unknown. We hypothesized that enhanced CXC chemokine secretion mediates
hepatic inflammation that accelerates development of HCC. Expandable primary human (upcyte®) hep-
atocytes and human PLC/PRF/5 hepatoma cells were lentivirally transduced with both PNPLA3 I148M
variants and stimulated with lipids. Cytokine levels in culture supernatant and patient sera (n = 80)
were analyzed by ELISA. Supernatants were assessed in transmigration experiments, tube formation, and
proliferation assays. In vitro, lipid stimulation of transduced hepatocytes dose-dependently induced the
production of interleukin-8 and CXCL1 in hepatocytes carrying the PNPLA3 148M variant. In line, sera
from PNPLA3 148M-positive patients with alcoholic liver cirrhosis contained higher levels of interleukin-
8 and CXCL1 than patients with wild-type PNPLA3. Supernatants from lipid-stimulated hepatocytes
with the PNPLA3 148M variant induced enhanced migration of white blood cells, angiogenesis, and cell
proliferation in comparison with supernatants from wild-type hepatocytes via CXC receptors 1 and 2.
Increased production of interleukin-8 and CXCL1 by hepatocytes carrying the PNPLA3 148M variant
contributes to a pro-inflammatory and tumorigenic milieu in patients with alcoholic liver disease. KEY
MESSAGES: The PNPLA3 148M variant is associated with cirrhosis and hepatocellular carcinoma. Lipid
stimulation of hepatocytes with this variant induces IL-8 and CXCL1. Supernatants from hepatocytes
with this variant promote migration and angiogenesis. Sera from patients with this variant contained
enhanced levels of IL-8 and CXCL1. The PNPLA3 148M variant contributes to a tumorigenic milieu via
IL-8 and CXCL1.
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Background: The I148M variant of the Patatin-like phospholipase domain-containing 
3 (PNPLA3) protein is associated with an increased risk for liver inflammation and 
hepatocellular carcinoma (HCC), but the underlying mechanism is unknown. We 
hypothesized that enhanced CXC chemokine secretion mediates hepatic 
inflammation that accelerates development of HCC. 
Methods: Expandable primary human (Upcyte®) hepatocytes and human 
PLC/PRF/5 hepatoma cells were lentivirally transduced with both PNPLA3 I148M 
variants and stimulated with lipids. Cytokine levels in culture supernatant and patients 
sera (n=80) were analysed by ELISA. Supernatants were assessed in transmigration 
experiments, tube formation and proliferation assays.  
Results: In-vitro, lipid stimulation of transduced hepatocytes dose-dependently 
induced the production of interleukin-8 and CXCL1 in hepatocytes carrying the 
PNPLA3 148M variant. In line, sera from PNPLA3 148M positive patients with 
alcoholic liver cirrhosis contained higher levels of interleukin-8 and CXCL1 than 
patients with wild-type PNPLA3. Supernatants from lipid-stimulated hepatocytes with 
the PNPLA3 148M variant induced enhanced migration of white blood cells, 
angiogenesis and cell proliferation in comparison to supernatants from wild-type 
hepatocytes via CXC receptor 1 and 2.  
Conclusion: Increased production of interleukin-8 and CXCL1 by hepatocytes 
carrying the PNPLA3 148M variant contributes to a pro-inflammatory and tumorigenic 
milieu in patients with alcoholic liver disease. 
 







































































Chronic liver disease is a major health burden leading to more than 1 million deaths 
per year in adults worldwide[1]. While the prevalence of liver diseases caused by 
infection with hepatitis B or C virus is likely to decline due to the availability of 
effective antiviral treatment, liver disease caused by alcoholic and non-alcoholic 
steatohepatitis is expected to become more frequent[2]. A common polymorphism in 
the Patatin like phospholipase domain containing 3 (PNPLA3) gene, leading to an 
exchange from isoleucine to methionine at position 148 (rs738409), is linked to 
progression of both alcoholic- and non-alcoholic liver disease[3, 4]. Presence of this 
variant increases the risk for fibrosis/cirrhosis[5, 6] and hepatocellular carcinoma 
(HCC) [7–9]. However, the underlying molecular mechanisms are not yet understood. 
The PNPLA3 protein acts as a triglyceride hydrolase, whose function is impaired by 
the I148M variant, resulting in hepatic triglycerides accumulation[10]. The presence 
of the 148M variant impairs the mobilization of triglycerides from lipid droplets by 
interfering with ubiquitylation and proteasomal degradation of the PNPLA3 protein, 
which causes the disease phenotype[11, 12]. In addition, PNPLA3 displays retinyl-
palmitate lipase activity in human stellate cells (HSC)[13]. Fat accumulation in the 
liver is associated with increased hepatic inflammation in patients with non-alcoholic 
fatty liver disease[14]. Importantly, patients carrying the PNPLA3 148M variant 
display higher transaminase levels even after adjustment for metabolic 
parameters[15], suggesting that increased intrahepatic inflammatory activity 
contributes to enhanced risk for cirrhosis and HCC in patients with the PNPLA3 148M 
variant. Experimental analysis of the so far unknown mechanism is hampered, 





































































over-expression of the PNPLA3 148M variant in mice or PNPAL3 148M knock-in 
mice develop liver steatosis when fed high-sucrose diet[17, 18]. 
Histologically, the presence of the PNPLA3 variant leads to more pronounced 
infiltration of leukocytes into the liver[6, 19]. Chronic inflammation precedes 
development of HCC in most cases[20]. Hepatocytes respond to lipids with 
production of significant amounts of inflammatory cytokines[21].  
Therefore, we tested if the presence of the PNPLA3 148M variant induces release of 
an inflammatory cytokine pattern in hepatocytes upon exposure to lipids, which may 
create a tumorigenic milieu in the liver. Thus, we analyzed expandable primary 
human hepatocytes and PLC/PRF/5 hepatoma cells lentivirally transduced with both 
PNPLA3 variants. 
 
Materials and Methods 
Cell culture  
Upcyte® human hepatocytes (UHH), a source of expandable, genetically-modified, 
primary, non-malignant hepatocytes, (upcyte technologies GmbH, Hamburg, 
Germany) are lentivirally transduced so that a switch between controlled proliferation 
and the differentiated primary phenotype can be induced by specific media without 
inducing immortalization. For proliferation, UHH were cultivated in collagen I-coated 
T-75 flasks with Hepatocyte Culture Medium (HCM) containing Supplement A, 
Supplement B and 2 mM L-glutamine (upcyte® technologies GmbH) as 
recommended by the manufacturer. After reaching confluency, cells were detached 
with trypsin and reseeded. To stop proliferation and induce re-differentiation to their 





































































coated 48-well plate and cultured in High Performance Medium (HPM=HCM without 
Supplement B) for 3 days before and during experiments. UHH cells from passage 
7-10 were used. In addition, PLC/PRF/5 hepatoma cells (LGC Standards GmbH, 
Wesel, Germany) were cultured in RPMI 1640 medium containing L-glutamine 
(Thermo Fisher, Schwerte, Germany), penicillin/streptomycin (PAN-Biotech GmbH, 
Aidenbach, Germany) and 10% fetal calf serum (FCS, Biochrom, Berlin, Germany) 
as a further control and cell model, which does not carry the limitations in cell 
proliferation of primary or expandable primary hepatocytes. HepG2 cells (LGC 
Standards GmbH) were cultured in RPMI 1640 medium containing L-glutamine, 
penicillin/streptomycin and 10% fetal calf serum.  
Molecular cloning, production and transduction of lentiviral constructs 
A lentiviral vector pLenti-GIII-CMV-GFP-2A-Puro containing cDNA coding for the 
PNPLA3 148M variant (Applied Biological Materials Inc., Vancouver, Canada) was 
converted to the 148I (G444A) consensus sequence using Quikchange Mutagenesis 
(Primer 5'-tggtatgttcctgcttcatacctttctacagtggc-3',   
5'-gccactgtagaaaggtatgaagcaggaacatacca-3'). Lentivirus was then generated via co-
transfection of the respective lentiviral plasmid with the second-generation packaging 
constructs pCMV delta R8.2 and pMD2.G /VSV-G (Trono Lab, Addgene, Cambridge, 
MA, USA) in HEK293FT cells (ThermoFisher Scientific, Carlsbad, California, USA) as 
previously described[22]. Transduction of upcyte® human hepatocytes and 
PLC/PRF/5 hepatoma cells was performed at MOI 10. Cells were selected with 
2µg/mL puromycin 96h after transduction. PNPLA3 overexpression was validated on 
the mRNA level by quantitative RT-PCR and on the protein level by western blot. 
Both showed a close correlation to the expression of the GFP reporter 





































































expression levels, we controlled GFP-expression by flow cytometry at each passage 
of cells. If the GFP-expression differed by more than 10%, it was adjusted by 
changing the puromycin concentration of the selection medium. 
 
Cytokine array 
To gain insights in differential cytokine regulation by upcyte® human hepatocytes 
(UHH) lentivirally transduced with PNPLA3 wildtype or I148M variant, we analysed 
supernatants with the Human XL Cytokine Array Kit (Bio-Techne, Wiesbaden, 
Germany) according to the manufacturer’s instructions. 
 
Cell stimulation 
Human hepatocytes were stimulated overnight with different concentrations of fetal 
calf serum (FCS) (1-20%), human serum albumin (HSA) (4%) (Octapharma, 
Langenfeld Germany) and palmitate (50µM). Lipid accumulation increased in cells 
stimulated with FCS when the PNPLA3 148M variant was present (supplementary 
figure 2). To test for possible involvement of endoplasmatic reticulum (ER) stress, 
5µM 4µ8C, an inhibitor of inositol requiring enzyme 1 (IRE1), and 300nM 
GSK2606414, an inhibitor of Protein Kinase RNA-like Endoplasmic Reticulum Kinase 
(PERK), respectively (both Merck Chemicals GmbH, Darmstadt, Germany), were 
added to some experiments 30 minutes before stimulation. As a positive control, ER 
stress was induced by incubating the cells with 2µg/ml tunicamycin. 
 





































































CXCL8/IL-8, CXCL1, CXCL4 and CXCL5 concentrations in patient sera and/or cell 
culture supernatants were assessed by the human IL-8 ELISA MAX™ (BioLegend, 
Fell, Germany), the human CXCL1/GROalpha, CXCL4/PF4 and CXCL5 DuoSet 
ELISA, (all Bio-Techne) according to the manufacturer’s protocols. 
 
Leukocyte transmigration assay 
A 96-well (3.0μm pore size) transmigration chamber (Corning, Wiesbaden, Germany) 
was used, adding 235µL of 1:5 diluted supernatants from FCS (15%) stimulated 
PLC/PRF/5 cells carrying either PNPLA3 148I or M variant to each well. RPMI 
medium alone was used as negative control. Then, 2x105 white blood cells (WBC), 
which were obtained from healthy donors after red blood cell lysis[23], were added in 
75µl RPMI medium to the top chamber. CXCR1 and CXCR2 blocking antibodies 
(clone 42705 and 48311, Bio-Techne) or an appropriate isotype control (clone 20102, 
Bio-Techne) were added at 10µl/ml to the WBC 30 min prior to incubation. Plates 
were incubated at 37°C for 2.5h, and cells migrating to the bottom chamber were 
quantified and classified into granulocytes, monocytes and lymphocytes based on 
size and granularity by flow cytometry on a BD FACS Canto II flow cytometer.  
Tube Formation Assay 
Measurements of capillary-like tube formation of HUVEC (PromoCell, Heidelberg) 
were performed with a MatrigelTM in vitro assay to assess angiogenetic potential of 
cell culture supernatants. HUVEC were cultured in starvation medium (Endothelial 
Cell Growth Medium without supplements; Provitro, Berlin) containing 1% FCS 
overnight prior to the experiment. Growth factor-reduced MatrigelTM (BD Biosciences, 





































































Munich) and incubated at 37°C for 1h. HUVEC were seeded in 40µl starvation 
medium containing 1% FCS at 6000/well. After 2h, medium was replaced by the 
respective supernatants from stimulation experiments with or without blocking 
antibodies against CXCR1 and CXCR2 at a final concentration of 10µg/ml. We used 
supernatants from UHH, because HUVEC cells as primary cells require additional 
factors for growth. Images were captured using a Axiovert 200M inverted 
microscope. Tube formation was quantified by counting the number of completely 
closed ring structures.  
Proliferation assay 
Proliferation assays were performed with the bromodeoxyuridine (BRDU) Flow Kit 
(BD Biosciences) according to the manufacturer’s instructions. In brief, HepG2 cells 
(2x104/well) were seeded and incubated for 24h in starvation medium (RPMI 1640 
+1% FCS) in a 48-well plate at 37°C and 5% CO2. The starvation medium was then 
replaced by conditioned supernatants. Incubation was continued overnight. CXCR1 
and CXCR2 were blocked by antibodies at 10µl/ml 30 min prior to incubation, using 
an appropriate isotype as control. Finally, 10µM BRDU were added for 30 min. Cells 
were then harvested, fixed, stained and analysed on a BD Canto II Flow Cytometer. 
Patients 
We collected serum from patients with alcoholic liver cirrhosis (n=80) and healthy 
controls (n=53) (table 1). Determination of the PNPLA3 rs738409 polymorphism was 
performed as previously described[7] 
Statistical analyses 
Experiments were performed in triplicates and repeated at least three times. 





































































test when comparing two and the non-parametric ANOVA (Friedman test) when 
comparing several groups. Test multiplicity was controlled by a false discovery 
rate (FDR) procedure (Benjamini, Krieger, Yetukieli) using GraphPad Prism 
Version 7 (GraphPad Software Inc, San Diego, CA, USA). FDR-adjusted P 
values <0.05 were considered statistically significant  
 
Results 
Hepatocytes carrying the PNPLA3 148M variant produce higher levels of CXCL1 and 
IL-8 
To analyze the functional role of the PNPLA3 I148M polymorphism at the molecular 
level, we lentivirally transduced both the wildtype (148I) and the 148M variant into 
expandable primary human hepatocytes (upcyte® hepatocytes, UHH). After re-
differentiation of the cells to their primary phenotype, we performed a cytokine screen 
which indicated enhanced secretion of CXCL1, CXCL4, CXCL5, CXCL8/IL-8, while 
CXCL10 was apparently downregulated. Subsequent quantitative studies by ELISA 
confirmed significantly increased production of CXCL1 and IL-8 in UHH with the 
PNPLA3 148M variant (Figure 1 A,B). By contrast, differences in the cytokine screen 
between hepatocytes carrying the 148I or 148M PNPLA3 variant were not 
reproduced concerning CXCL4 (810pg/ml vs 901pg/ml; p=0.22,), CXCL5 (39.8ng/ml 
vs 39.0ng/ml; p=0.96) or CXCL10 (497pg/ml vs 474pg/ml; p=0.65). To check whether 
increased IL-8 and CXCL1 production could be confirmed in a standard hepatoma 
line, we transduced the PNPLA3 148M variant into PLC/PRF/5 human hepatoma 
cells, which unlike many other hepatoma lines such as Huh7 or HepG2 do not 





































































variants in transduced PLC/PRF/5 human hepatoma cells, the same pattern of 
differentially produced IL-8 and CXCL1 was observed (Figure 1 C,D). Conversely, 
when we silenced PNPLA3 in Huh7 liver cells which constitutively carry the 
PNPLA3 148M/M variant, we found decreased secretion of IL-8 (supplementary 
figure 3). 
To analyze if IL-8 and CXCL1 production was stimulated by exposure to lipids, we 
added palmitate as well as lipid carriers (FCS and HSA) to the transduced 
hepatocytes. Chemokine levels in PNPLA3 148M positive cells significantly exceeded 
the amounts in cells transduced with PNPLA3 wildtype (148I) (Figure 2 A-D). 
Exposure to lipids induced release of IL-8 and CXCL1 in a dose dependent fashion 
(Figure 2 E, F).  
Patients carrying a PNPLA3 148M allele display higher circulating levels of CXC-
chemokines IL-8 and CXCL1, but not CXCL5 
To verify if the PNPLA3 148M variant also leads to differences in chemokine levels 
in-vivo, we measured serum levels of IL-8, CXCL1 and CXCL5 both in healthy 
controls and patients with alcoholic liver cirrhosis stratified for PNPLA3 genotype 
(demographic and clinical details are given in table 1). As displayed in figure 3, we 
found comparatively low serum levels independent of the PNPLA3 genotype in 
healthy controls, while patients with liver cirrhosis revealed significantly increased IL-
8 (p=0.011) and CXCL1 (p=0.012) serum levels in carriers of the PNPLA3 148M 
variant. These results remained significant after correction for severity of liver 
cirrhosis (Child-Pugh stage) or presence of HCC (n=14) (IL-8 p=0.03, CXCL1 
p=0.03). By contrast, CXCL5 levels did not differ between carriers of the PNPLA3 





































































Differences in IL-8 and CXCL1 secretion cannot be attributed to increased ER stress 
in hepatocytes with the PNPLA3 148M variant  
Lipid overload in hepatic cells induces endoplasmatic reticulum (ER) stress[24], 
which might be aggravated by the accumulation of the PNPLA3 protein due to its 
impaired degradation in presence of the  PNPLA3 148M variant[11]. We suspected 
that ER stress might cause the increased IL-8 and CXCL1 secretion in hepatocytes 
carrying the PNPLA3 148M variant. Therefore, we treated 15% FCS stimulated 
PLC/PRF/5 with either 4µ8C, an inhibitor of IRE1, or GSK2606414, an inhibitor of 
PERK, which block two major downstream-signaling pathways linking ER stress to 
cytokine regulation. However, although the inhibitors reduced IL-8 production in 
response to tunicamycin, a positive control agent known to induce ER stress, none of 
the inhibitors blocked the excess of IL-8 production seen in hepatocytes carrying the 
PNPLA3 148M variant (Figure 4). Thus, differences in ER stress are unlikely to 
explain differential IL-8 production by hepatocytes depending on the PNPLA3 148 
genotype. 
Supernatants from PNPLA3 148M positive hepatocytes induced enhanced 
chemotaxis in leukocytes 
To check if differential cytokine expression by hepatocytes carrying the two different 
PNPLA3 variants contributed to a pro-inflammatory and ultimately oncogenic milieu, 
we first investigated whether supernatants from stimulated, PNPLA3-transduced 
PLC/PRF/5 cells were chemotactic for leukocytes using a transmigration assay with 
conditioned supernatants and leukocytes from healthy donors. Both supernatants 
from hepatocytes with and without the PNPLA3 148M variant induced migration of 
leukocytes, but supernatants from hepatocytes carrying the PNPLA3 148M variant 





































































(Figure 5B-D). Blocking CXCR1 and CXCR2, the shared receptors for CXCL1 and 
IL-8, inhibited the enhanced migration towards supernatant from cells carrying the 
PNPLA3 148M variant.  
Supernatants from hepatocytes with a PNPLA3 I148M variant are angiogenic 
To assess if the PNPLA3 I148M polymorphism promotes angiogenesis, we used 
supernatants from lipid-stimulated UHH in a tube formation assay. Supernatant from 
lipid-stimulated UHH with the 148M variant led to increased tube formation as 
compared to supernatants from UHH with the 148I variant or from untransduced UHH 
(Figure 6 A-C). Of note, this difference was abolished by blocking CXCR1 and 
CXCR2, suggesting that CXC-chemokines such as IL-8 and CXCL1 mediate 
enhanced angiogenesis in presence of the PNPLA3 I148M variant. 
Supernatants from hepatocytes with a PNPLA3 I148M variant increase the 
proliferation of HepG2 cells 
We then wondered whether supernatants of hepatocytes carrying the PNPLA3 I148M 
variant might increase proliferation in hepatocytes that have already undergone 
malignant transformation, such as HepG2 cells. Proliferation of HepG2 cells was 
induced to a greater extent by supernatants from FCS-stimulated PLC/PRF/5 cells 
carrying the PNPLA3 148M variant compared to the PNPLA3 148I wild-type. Again, 
this effect could be abrogated by blocking CXCR1 and CXCR2, suggesting that CXC 
chemokines induced by the PNPLA3 148M variant induce proliferation in susceptible 







































































Carriage of the PNPLA3 148M variant has been associated with the progression and 
severity of metabolic liver disease in multiple studies[25, 26]. Since patients with liver 
disease and the PNPLA3 148M variant are characterized by increased intrahepatic 
leukocyte counts[6, 19] and based on our exploratory cytokine array analysis, we 
hypothesized that CXC-chemokines might mediate increased liver inflammation in 
patients carrying the PNPLA3 148M variant by attracting leukocytes and ultimately 
create a tumorigenic milieu. Production of CXC-chemokines by hepatocytes in 
response to lipids has already been demonstrated by other groups[21]. Here, we add 
the information that carriage of the PNPLA3 148M variant increases IL-8 and CXCL1 
production by hepatocytes in response to lipids, irrespective if the cells were exposed 
to free fatty acids, such as palmitate, or to lipid carriers such as FCS or HSA. In 
addition to acting as a lipid carrier, albumin may induce IL-8 secretion by 
activating the epidermal growth factor receptor (EGFR)[27], which may explain 
in part the high secretion of IL-8 even in cells carrying the PNPLA3 wildtype. As 
a particular strength of our study, we used genetically modified primary hepatocytes 
(upcyte® hepatocytes, UHH) to mimic the in-vivo situation as closely as possible. We 
found differential IL-8 and CXCL1 production both in UHH and a human hepatoma 
cell line (PLC/PRF/5) when they were transduced with either the PNPLA3 148I or 
148M variant. The link between production of inflammatory chemokines and 
carriage of the PNPLA3 148M variant was further strengthened by the fact that 
silencing of PNPLA3 148M in Huh7 cells reduced expression of IL-8. In line, 
Linden et al. described reduced production of inflammatory cytokines and 
decreased fibrosis when PNPLA3 was silenced in a PNPLA3 148M knock-in 
mouse model of hepatic steatosis[28]. Unlike previous reports from HSC, we did 
not detect differences in expression of CCL2 or CCL5 in relation to the PNPLA3 





































































hepatocytes and HSC. Our in-vitro findings corresponded to differential IL-8/CXCL1 
serum levels in patients with alcoholic liver cirrhosis when they were stratified with 
respect to the PNPLA3 genotype. 
The mechanism linking the PNPLA3 148M variant to the increased induction of CXC 
chemokines remains unclear. Perturbation of the normal function of endoplasmatic 
reticulum (ER) leads to ER stress, which has been implicated in liver disease of 
different etiologies and HCC development[30] and results in activation of NFB and 
production of inflammatory mediators, among others IL-8, via inositol-requiring 
enzyme 1 (IRE1)[31] or via PERK/CHOP signaling[32]. Lipid overload has been 
reported to induce chronic ER stress[24], which might be further increased by 
impaired degradation of the PNPLA3 protein in presence of the 148M variant[11]. We 
therefore hypothesized that blocking the ER stress sensors IRE1 or PERK might 
abrogate the enhanced IL-8 secretion in PNPLA3 148M positive hepatocytes. 
Contrary to our expectations, inhibition of IRE1 or PERK did not block the increased 
IL-8 secretion detected in PNPLA3 148M positive cells, while either inhibitor reduced 
IL-8 secretion induced by tunicamycin. Alternative plausible causes for enhanced IL-8 
and CXCL1 induction might be oxidative stress by lipid overload or lipid toxicity[31]. 
Increased IL-8 and CXCL1 production in response to lipid exposure in hepatocytes 
with the PNPLA3 148M variant could explain several findings observed in PNPLA3 
148M positive patients with fatty liver disease: increased intrahepatic leukocyte 
content may be due to chemotaxis by IL-8 and CXCL1, which enhance angiogenesis 
and proliferation, promoting malignant transformation towards development of HCC. 
Of note, it has been shown that HCC progresses more rapidly in patients carrying the 
PNPLA3 148M variant independent of other risk factors[33, 34]. Migration 





































































migration of leukocytes, in particular granulocytes, to a greater extent in carriers of 
the PNPLA3 148M variant than in carriers of the wild-type. Of note, this difference 
was dependent on the CXC chemokine receptors 1 and 2. To substantiate the 
connection between the PNPLA3 148M variant, CXC chemokine secretion, and 
promotion of hepatic malignancy, we studied supernatants from stimulated 
hepatocytes in angiogenesis and proliferation assays. In short, we found that 
supernatants from the PNPLA3 148M hepatocytes increased angiogenesis in 
HUVEC cells and proliferation of HepG2 cells, providing further support for the 
concept that this genetic variant leads to a microenvironment which promotes tumor 
growth. Again, increased angiogenesis and proliferation could be abolished by 
blocking CXCR1 and CXCR2. CXCR1 and CXCR2 are the receptors for CXCL1 and 
IL-8, but can also bind CXCL6 and CXCL2-3/CXCL5-6, so that we cannot completely 
rule out that other CXC chemokines might be involved as well[35]. For instance, 
CXCL5 may promote development of HCC[36, 37]. However, we did not detect a 
differential CXCL5 pattern neither in cell supernatants nor in patient sera. 
CXC chemokines are known to be important mediators of leukocyte invasion in liver 
disease[38]. CXCL1 and IL-8 have already been linked to fibrosis development[39, 
40]. Previously, we demonstrated that a genetic variant in the CXCL1 gene was 
associated with increased serum levels of CXCL1 and that this variant was more 
frequent among patients with alcoholic liver cirrhosis and HCC[40]. Serum levels of 
both CXCL1 and CXCL8/IL-8 have been reported as biomarkers for HCC[41, 42], 
with serum IL-8 being also an independent predictor of survival in patients with 
HCC[43]. Intrahepatic expression of CXCL1 is a risk factor for mortality and 
recurrence of HCC[44, 45], while silencing CXCL1 reduced tumor growth in an in-





































































metastases via the transcription factor forkhead box C1[47]. Unfortunately, analysis 
of the IL-8 dependent oncogenic effect of the PNPLA3 148M genotype in animal 
models is not possible, because mice lack IL-8.  
A detailed knowledge of the molecular pathways involved in mediating the negative 
effects of the PNPLA3 mutation would help to identify targets for prevention of HCC. 
This is important, because lifestyle modifications offer an effective treatment by 
reducing body weight in patients affected by the PNPLA3 mutation[48], but the HCC 
risk remains elevated[49]. Because the PNPLA3 148M variant increases the risk for 
complications across different etiologies of liver disease[50], pharmacological 
modulation of such targets might be beneficial for a wide range of patients. Here, we 
present evidence that CXC chemokines are excessively produced in response to 
lipids by hepatocytes that carry the PNPLA3 148M variant, which may contribute to 
the development of liver cancer. Further elucidation of the mechanistic consequence 
of this genetic alteration will hopefully help us to progress from merely identifying 
patients at particular risk to targeted prophylactic interventions in order to prevent 
HCC. 
 
Compliance with ethical standards 
The study protocol was approved by the ethics committee of the University of Bonn 
(number 351/15) and complied with the ethical guidelines given by the Declaration of 
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Fig. 1: Increased basal production of unstimulated human hepatocytes 
carrying the PNPLA3 148M variant. 
Levels of IL-8 (A+C) and CXCL1 (B+D) in the supernatant of unstimulated upcyte® 
human hepatocytes (A+B) and PLC/PRF/5 (C+D) carrying the PNPLA3 148I wild-
type or 148M variant after overnight incubation. Statistical analysis with non-
parametric ANOVA (Friedman test). Error bars indicate SEM. 
 
Fig. 2: The enhanced CXC chemokine production of human hepatocytes with 
the PNPLA3 148M variant increases alongside with lipid availability. 
IL-8 (A, C) and CXCL1 (B, D) levels in the supernatant of upcyte® human 
hepatocytes cells (A, B) or PLC/PRF/5 (C, D) stratified for PNPLA3 I148M 
genotype after overnight stimulation with fetal calf serum (FCS), human serum 
albumin (HSA) or palmitate; the IL-8 (E) and CXCL1 (F) production is dose 
dependent of FCS concentration, as exemplarily shown for PLC/PRF/5 cells. 
Statistical analysis with Mann-Whitney-U test. Error bars indicate SEM. 
 
Fig. 3: Serum levels of CXCL1 and IL-8 are increased in patients with alcoholic 
liver cirrhosis carrying the PNPLA3 148M variant. 
Serum levels of IL-8 (A), CXCL1 (B) and CXCL5 (C) were measured by ELISA in the 
serum of patients with alcoholic liver cirrhosis and healthy controls stratified 
according to the PNPLA3 genotype. Statistical analysis with Mann-Whitney-U 





































































Fig. 4: The increased IL-8 production of hepatocytes carrying the PNPLA3 
I148M variant is not mediated by PERK or IRE1 
While IL-8 production after induction of ER stress in PLC/PRF/5 cells by tunicamycin 
as a positive control was prevented by inhibitors of PERK or IRE1, both inhibitors did 
not have an effect on IL-8 production induced by 15% FCS in PNPLA3 148M positive 
cells. Statistical analysis with Mann-Whitney-U test. Error bars show SEM. 
 
Fig. 5: Leukocytes migrate preferentially versus supernatant from hepatocytes 
carrying the PNPLA3 148M variant. 
Using a transwell chamber assay, migration of healthy human leukocytes versus 1:5 
diluted supernatant from 15% FCS stimulated PLC/PRF/5 cells was assessed by flow 
cytometry. (A) Summary graph show the enhanced migration versus supernatant 
from hepatocytes carrying the PNPLA3 148M variant, which is mediated via 
receptors CXCR1 and CXCR2. Representative forward/sideward scatter plots of 
leukocytes before (B) and after migration (C+D) to the bottom well against 
supernatant from cells with the PNPLA3 148I (C) and 148M (D) variant. Statistical 
analysis with non-parametric ANOVA (Friedman test). Error bars indicate SEM. 
 
Fig. 6: Supernatants from human hepatocytes carrying the PNLPA3 148M 
variant increase angiogenesis and proliferation. 
Angiogenetic potential was assessed by a tube formation assay (A-C). Human 
umbilical vein endothelial cells (HUVEC) formed more tubes if treated with 





































































variant compared to the wild-type in a CXCR1 and CXCR2 dependent manner. 
Representative microscopic images from wild-type supernatants (A) and PNPLA3 
148M variant supernatants (B) and summary graph (C). 
Proliferation of HepG2 cells as assessed by bromodeoxyuridine (BRDU) 
incorporation increased in the presence of supernatant from stimulated PLC/PRF/5 
carrying the PNPLA3 148M variant compared to the 148I wild-type in a CXCR1 and 
CXCR2 dependent manner. (D) Statistical analysis with non-parametric ANOVA 
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Figure 6
Table 1. Demographic and Clinical Data of the Study Groups 
    
Alcoholic 
cirrhosis      
(n=80) 
Alcoholic 










Healthy       
controls     
(n=53) 
Median age, years 
(range) 
57 (27-80) 56,5 (27-80) 57 (36-73) 0.53 34 (22-70) * 
Gender (% male/female) 66.3 / 33.7 65.6 / 34.4 66.7 / 33.3 0.92   42 / 58 * 
MELD, (Mean ± SD) 13.31 ± 5.1 12.7 ± 5.3 13.7 ± 5.0 0.44 - 
Child-Pugh class               
A/B/C (%)  
21/56/23 25/59/16 19/54/27 0.46 - 
Bilirubin [mg/dl],           
(Mean ± SD)  
3.04 ± 4.93 3.25 ± 4.81    2.90 ± 5.06 0.76 - 
Platelet count [*103/µl], 
(Mean ± SD)  
132 ± 64 137 ± 61 128 ± 66 0.54 - 
ALT [IU/l], (Mean ± SD) 
 
47.9 ± 46.6  54.4 ± 62.8    43.6 ± 31.7 0.31 - 
AST [IU/l], (Mean ± SD)   75.5 ± 71.4  83.0 ± 98.7   70.5 ± 45.6 0.45 - 
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